干旱区生态环境知识资源中心(Arid): A Novel Immunotype-based Risk Stratification Model Predicts Postoperative Prognosis and Adjuvant TACE Benefit in Chinese Patients with Hepatocellular Carcinoma

Arid

DOI	10.7150/jca.54408
	A Novel Immunotype-based Risk Stratification Model Predicts Postoperative Prognosis and Adjuvant TACE Benefit in Chinese Patients with Hepatocellular Carcinoma
	Li, Tian-En; Zhang, Ze; Wang, Yi; Xu, Da; Dong, Jian; Zhu, Ying; Wang, Zheng
通讯作者	Wang, Z (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Comprehens Breast Hlth Ctr, Dept Gen Surg,Sch Med, Shanghai 200025, Peoples R China. ; Zhu, Y (corresponding author), Fudan Univ, Huashan Hosp, Dept Gen Surg, Shanghai 200040, Peoples R China. ; Zhu, Y (corresponding author), Fudan Univ, Canc Metastasis Inst, Shanghai 200040, Peoples R China.
来源期刊	JOURNAL OF CANCER
ISSN	1837-9664
出版年	2021
卷号	12 期号:10 页码:2866-2876
英文摘要	Background and Aims: The tumor microenvironment can be divided into inflamed, immune-excluded and immune-desert phenotypes according to CD8(+) T cell categories with differential programmed cell death protein 1 (PD-L1) expression. The study aims to construct a novel immunotype-based risk stratification model to predict postsurgical survival and adjuvant trans-arterial chemoembolization (TACE) response in patients with hepatocellular carcinoma (HCC). Methods: A total of 220 eligible HCC patients participated in this study. CD8(+) T cell infiltration and PD-L1 expression mode were estimated by immunohistochemical staining. A risk stratification model was developed and virtualized by a nomogram that integrated these independent prognostic factors. The postoperative prognosis and adjuvant TACE benefits were evaluated with a novel immunotype-based risk stratification model. Results: A total of 220 patients were finally identified. Immune-desert, immune-excluded, and inflamed immunotypes represented 45%, 24%, and 31% of HCC, respectively. Univariate and multivariate analyses identified immunotype and PD-L1 expression mode as independent prognostic factors for overall survival time (OS) and recurrence-free survival time (RFS). The nomogram was constructed by integrating immunotype, PD-L1 expression, Barcelona Clinic Liver Cancer (BCLC) stage and tumor grade. The C-index was 0.794 in the training cohort and 0.813 in the validation cohort. A risk stratification system was constructed based on the nomogram classifying HCC patients into 3 risk groups. The average OS times in the low-risk, intermediate-risk and high-risk groups in all cohorts were 77.1 months (95% CI 71.4-82.9), 53.7 months (95% CI 48.2-59.2), and 25.6 months (95% CI 21.4-29.7), respectively. Further analysis showed that OS was significantly improved by adjuvant TACE in the low- and intermediate-risk groups (P=0.041 and P=0.010, respectively) but not in the high-risk group (P=0.398). Conclusion: A novel immunotype-based risk stratification model was built to predict postoperative prognosis and adjuvant TACE benefit in HCC patients. These tools can assist in building a more customized method of HCC treatment.
英文关键词	Hepatocellular carcinoma adjuvant TACE tumor microenvironment immunotype prognosis
类型	Article
语种	英语
开放获取类型	gold, Green Published
收录类别	SCI-E
WOS记录号	WOS:000637323300008
WOS类目	Oncology
WOS研究方向	Oncology
资源类型	期刊论文
条目标识符	http://119.78.100.177/qdio/handle/2XILL650/350748
作者单位	[Wang, Zheng] Shanghai Jiao Tong Univ, Ruijin Hosp, Comprehens Breast Hlth Ctr, Dept Gen Surg,Sch Med, Shanghai 200025, Peoples R China; [Li, Tian-En] Shandong Univ, Qilu Hosp, Dept Gen Surg, Jinan 250012, Peoples R China; [Zhang, Ze; Wang, Yi; Xu, Da; Zhu, Ying] Fudan Univ, Huashan Hosp, Dept Gen Surg, Shanghai 200040, Peoples R China; [Zhang, Ze; Wang, Yi; Xu, Da; Zhu, Ying] Fudan Univ, Canc Metastasis Inst, Shanghai 200040, Peoples R China; [Dong, Jian] Xi An Jiao Tong Univ, Affiliated Hosp 1, Inst Adv Surg Technol & Engn, Med Coll, Xian 710061, Peoples R China
推荐引用方式 GB/T 7714	Li, Tian-En,Zhang, Ze,Wang, Yi,et al. A Novel Immunotype-based Risk Stratification Model Predicts Postoperative Prognosis and Adjuvant TACE Benefit in Chinese Patients with Hepatocellular Carcinoma[J],2021,12(10):2866-2876.
APA	Li, Tian-En.,Zhang, Ze.,Wang, Yi.,Xu, Da.,Dong, Jian.,...&Wang, Zheng.(2021).A Novel Immunotype-based Risk Stratification Model Predicts Postoperative Prognosis and Adjuvant TACE Benefit in Chinese Patients with Hepatocellular Carcinoma.JOURNAL OF CANCER,12(10),2866-2876.
MLA	Li, Tian-En,et al."A Novel Immunotype-based Risk Stratification Model Predicts Postoperative Prognosis and Adjuvant TACE Benefit in Chinese Patients with Hepatocellular Carcinoma".JOURNAL OF CANCER 12.10(2021):2866-2876.